Fanhua announced that it, through its wholly-owned subsidiary Fanhua BluePlus Health Management Co., Ltd. has recently signed a strategic cooperation agreement with Shanghai Biotecan Pharmaceuticals Co. Ltd. Pursuant to the strategic cooperation agreement, Fanhua BluePlus and Biotecan will leverage their respective resources and service strengths to collaborate on cutting-edge medical testing, health management, cell therapy, and other modern high-end medical and health management services.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FANH:
- Fanhua to Unveil H1 2024 Financial Outlook
- Fanhua to Announce 2024 First Half Unaudited Financial Results on September 18, 2024
- Fanhua Key Employees Bet Big on Future
- Fanhua announces completion of share option cash exercises
- Fanhua Announces Completion of Share Option Cash Exercises by Key Employees